Biotech Startup Cheiron Scores $8M in Seed Funding Round

The round also saw participation from Moderna co-founder and MIT Institute Professor Robert Langer; former Pfizer Chief Medical Officer Freda Lewis-Hall; Chai Discovery co-founder and CEO Josh Meier; former Starbucks CEO Laxman Narasimhan; and former Apple AI chief John Giannandrea. Venky Ganesan, Partner at Menlo Ventures, is joining Cheiron’s board.

The company will use the funding to expand its Life Sciences Knowledge Graph, improve its platform for clinical, regulatory, and business workflows, and grow its engineering, product, and life sciences teams.

Read More:AI Startup Cast Insights Bags $4.5M in Pre-Seed Funding

Cheiron is building an AI-powered operating system that brings every part of a drug development program into one connected platform. Less than six months after its launch, the platform has been adopted by tens of thousands of biopharma professionals and is already being used by major drug development companies.

Cheiron uses AI to bring all parts of a drug development program into one connected system. It helps teams track data, decisions, risks, and progress in a single place. Recent advances in AI and knowledge technology have made it possible for teams to better understand and manage the entire drug development process.

“Cheiron helps us move beyond searching across fragmented sources toward understanding the full state of a program,” said Jung Gyun Kim, CEO at Boryung, one of the top five pharmaceutical companies in Korea that has already deployed Cheiron. “By connecting evidence, assumptions, risks, and decisions in one place, the platform gives teams a clearer way to evaluate programs, and support critical decisions.”

“Minseok and the team didn’t build another search tool for life sciences — they rethought what a drug program actually is,” said Venky Ganesan, Partner at Menlo Ventures, who is joining Cheiron’s board. “Cheiron gives drug developers a single, structured view of the evidence, assumptions, risks, decisions, and commitments behind an entire program. That has the potential to become foundational infrastructure for how therapies are developed.

“Discovery gets much of the attention, but execution ultimately determines how quickly new medicines reach patients,” said Robert Langer, Co-Founder, Moderna. “Technologies like Cheiron, which help compress development timelines across the drug lifecycle, can play an important role in accelerating that process.”

About Cheiron

Founded in 2024, by Minseok Bae, Jason Park, and Harshit Gupta, Cheiron is an AI powered platform built for drug development. Its platform helps biopharma teams manage the entire drug development process by organizing data, evidence, risks assumptions and key decisions in one place, making it easier to evaluate, and advance new therapies.

Read More:California-Based Coverwatch Bags $4.5M in Pre-Seed Funding